RNA Immune Signatures From Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers

Cancers - Switzerland
doi 10.3390/cancers12030620
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer

Frontiers in Genetics
GeneticsMolecular Medicine
2020English

New in High Grade Serous Ovarian Cancer Treatment

Effective Pharmacotherapy
2019English

Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors

PLoS ONE
Multidisciplinary
2009English

Integrated Analysis to Identify Molecular Biomarkers of High-Grade Serous Ovarian Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Small RNAs and the Competing Endogenous RNA Network in High Grade Serous Ovarian Cancer Tumor Spread

Oncotarget
Oncology
2016English

Thrombocytosis and Hyperfibrinogenemia Are Predictive Factors of Clinical Outcomes in High-Grade Serous Ovarian Cancer Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy